ATRA · Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Cap structure and valuation
| Cap structure | |
|---|---|
| SP | $8.47 |
| SO | 9.0M |
| Options | 5.2M |
| Warrants | 6.4M |
| FD SO | 20.6M |
| MC | $174.7M |
| Cash | $8.4M |
| Total debt | — |
| EV | $166.3M |
| TTM Multiples | |
|---|---|
| EV / Revenue | 7.2x |
| EV / EBITDA | — |
| MC / Net Income | — |
| EV / FCF | — |
| MC / FCF | — |
| Ownership & coverage | |
|---|---|
| Institutional | 52.5% |
| Insiders | 16.9% |
| # Institutions | 46 |
| Analysts | 3 |
| Consensus | — |
| Avg target | $13.67 |
| Short % float | 5.7% |
| Days to cover | 4.22 |
MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-05-08. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative, or when fewer than four quarters are reported — a partial sum is not a trailing twelve months. Ownership & coverage per Yahoo Finance as of 2026-07-13 — institutional % is 13F-based, so it can lag a quarter and exceed 100% on share-count timing. Short interest per FINRA bi-monthly reporting, as of 2026-06-29; the float denominator can be unreliable on tiny floats.
Financial statements
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Total Revenue | 0.52 | 1.59 | 3.45 | 17.57 |
| Revenue YoY % | (99.5%) | (95.1%) | (91.4%) | (38.6%) |
| Gross Profit | (0.78) | (0.79) | (0.70) | 9.71 |
| Gross Profit YoY % | (101.5%) | (89.0%) | 2.6% | 1295.9% |
| Gross Margin % | (150.4%) | (49.8%) | (20.4%) | 55.3% |
| SG&A | 3.60 | 4.28 | 3.99 | 6.51 |
| R&D | 0.16 | (0.22) | 2.92 | 7.31 |
| Operating Income | (3.37) | (2.56) | (3.57) | 3.20 |
| Operating Income YoY % | (108.7%) | 79.0% | 83.6% | 117.5% |
| Operating Margin % | (652.9%) | (160.7%) | (103.5%) | 18.2% |
| EBITDA | (3.34) | (2.51) | (3.54) | 3.43 |
| EBITDA Margin % | (647.3%) | (157.6%) | (102.5%) | 19.5% |
| Interest Expense | 0.83 | 0.89 | 0.91 | 0.97 |
| Pretax Income | (4.14) | (3.41) | (4.28) | 2.39 |
| Tax Provision | 0.00 | 0.00 | 0.03 | 0.00 |
| Net Income | (4.14) | (3.41) | (4.30) | 2.39 |
| Net Margin % | (803.3%) | (213.5%) | (124.6%) | 13.6% |
| Diluted EPS | -$0.29 | -$0.36 | -$0.32 | $0.19 |
| Basic EPS | -$0.29 | -$0.35 | -$0.32 | $0.20 |
| Diluted Avg Shares | 14.1 | — | 13.6 | 12.3 |
| Basic Avg Shares | 14.1 | — | 13.6 | 12.2 |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Total Revenue | 23.14 | 120.77 | 128.94 | 8.57 | 63.57 |
| Revenue YoY % | (80.8%) | (6.3%) | 1404.0% | (86.5%) | — |
| Gross Profit | 7.44 | 62.12 | (2.50) | 0.14 | 2.69 |
| Gross Profit YoY % | (88.0%) | 2579.6% | (1876.6%) | (94.8%) | — |
| Gross Margin % | 32.1% | 51.4% | (1.9%) | 1.6% | 4.2% |
| SG&A | 18.38 | 26.25 | 39.89 | 50.91 | 71.55 |
| R&D | 10.18 | 37.45 | 151.48 | 224.78 | 272.53 |
| Operating Income | (6.31) | 35.86 | (83.44) | (276.01) | (280.51) |
| Operating Income YoY % | (117.6%) | 143.0% | 69.8% | 1.6% | — |
| Operating Margin % | (27.3%) | 29.7% | (64.7%) | (3219.5%) | (441.2%) |
| EBITDA | (5.96) | 37.98 | (78.39) | (271.18) | (274.86) |
| EBITDA Margin % | (25.8%) | 31.4% | (60.8%) | (3163.2%) | (432.4%) |
| Interest Expense | 3.60 | 3.79 | 4.62 | 5.29 | 0.37 |
| Other Income / (Expense) | — | 0.65 | 2.64 | 5.18 | 52.60 |
| Pretax Income | (9.44) | 32.72 | (85.42) | (276.11) | (228.29) |
| Tax Provision | 0.03 | 0.03 | (0.01) | 0.01 | 0.01 |
| Net Income | (9.47) | 32.69 | (85.40) | (276.13) | (228.30) |
| Net Margin % | (40.9%) | 27.1% | (66.2%) | (3220.9%) | (359.1%) |
| Diluted EPS | -$0.78 | $2.57 | -$11.41 | -$65.19 | -$2.24 |
| Basic EPS | -$0.76 | $2.61 | -$11.41 | -$65.19 | -$2.24 |
| Diluted Avg Shares | 14.1 | 12.7 | 7.5 | 4.2 | 102.0 |
| Basic Avg Shares | 14.1 | 12.5 | 7.5 | 4.2 | 102.0 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Cash & Equivalents | 8.36 | 8.48 | 5.74 | 16.90 |
| Short-term Investments | — | 0.00 | 7.97 | 5.42 |
| Receivables | 0.00 | 1.25 | 1.91 | 0.00 |
| Inventory | — | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 3.81 | 2.48 | 2.81 | 2.45 |
| Total Current Assets | 12.17 | 12.21 | 18.43 | 24.77 |
| Net PPE | 0.06 | 0.07 | 0.15 | 0.18 |
| Operating Lease ROU | 6.88 | 7.06 | 10.71 | 11.03 |
| Other Assets | 0.89 | 0.89 | 0.88 | 0.93 |
| Total Assets | 20.00 | 20.23 | 30.17 | 36.90 |
| Accounts Payable | 0.64 | 0.13 | 0.32 | 1.76 |
| Current Lease Liabilities | 1.01 | 1.03 | 1.95 | 2.24 |
| Other Current Liabilities | 3.99 | 13.77 | 15.79 | 10.56 |
| Total Current Liabilities | 5.64 | 14.92 | 18.06 | 14.56 |
| Long-term Lease Liabilities | 9.08 | 9.35 | 15.01 | 15.43 |
| Other Liabilities | 42.59 | 34.47 | 33.74 | 41.95 |
| Total Liabilities | 57.31 | 58.74 | 66.80 | 71.94 |
| Retained Earnings | (2,026.01) | (2,021.87) | (2,018.46) | (2,014.16) |
| Total Equity | (37.31) | (38.50) | (36.63) | (35.04) |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.36 | 8.48 | 25.03 | 25.84 | 92.94 |
| Short-term Investments | — | 0.00 | 17.47 | 25.88 | 149.88 |
| Receivables | 0.00 | 1.25 | 1.48 | 34.11 | 40.22 |
| Inventory | — | 0.00 | 10.65 | 9.71 | 1.59 |
| Other Current Assets | 3.81 | 2.48 | 10.26 | 6.33 | 10.45 |
| Total Current Assets | 12.17 | 12.21 | 64.89 | 101.87 | 295.08 |
| Net PPE | 0.06 | 0.07 | 1.29 | 3.86 | 6.30 |
| Operating Lease ROU | 6.88 | 7.06 | 39.81 | 54.94 | 68.02 |
| Other Assets | 0.89 | 0.89 | 3.10 | 4.84 | 7.02 |
| Total Assets | 20.00 | 20.23 | 109.10 | 165.50 | 376.42 |
| Accounts Payable | 0.64 | 0.13 | 4.37 | 3.68 | 6.87 |
| Current Lease Liabilities | 1.01 | 1.03 | 12.88 | 11.26 | 12.81 |
| Other Current Liabilities | 3.99 | 13.77 | 117.33 | 127.28 | 59.24 |
| Total Current Liabilities | 5.64 | 14.92 | 134.57 | 142.23 | 78.92 |
| Long-term Lease Liabilities | 9.08 | 9.35 | 29.91 | 45.69 | 58.06 |
| Other Liabilities | 42.59 | 34.47 | 41.89 | 76.82 | 112.80 |
| Total Liabilities | 57.31 | 58.74 | 206.38 | 264.74 | 249.78 |
| Retained Earnings | (2,026.01) | (2,021.87) | (2,054.55) | (1,969.15) | (1,693.02) |
| Total Equity | (37.31) | (38.50) | (97.28) | (99.23) | 126.64 |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Net Income | (4.14) | (3.41) | (4.30) | 2.39 |
| D&A | 0.03 | 0.05 | 0.04 | 0.24 |
| Stock-Based Comp | 0.75 | 1.52 | 1.23 | 2.80 |
| Δ Working Cap & Other | 0.29 | (3.86) | (6.75) | (12.74) |
| Operating Cash Flow | (3.07) | (5.70) | (9.79) | (7.32) |
| CapEx | — | 0.00 | 0.00 | 0.00 |
| Other Investing | — | 8.44 | (2.42) | (5.07) |
| Investing Cash Flow | 0.00 | 8.44 | (2.42) | (5.07) |
| Stock Issuance | 2.95 | (0.03) | 1.50 | 0.00 |
| Other Financing | — | — | — | 15.30 |
| Financing Cash Flow | 2.95 | (0.00) | 1.05 | 15.30 |
| Free Cash Flow | — | (5.70) | (9.79) | (7.32) |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Net Income | (9.47) | 32.69 | (85.40) | (276.13) | (228.30) |
| D&A | 0.35 | 2.12 | 5.05 | 4.83 | 5.65 |
| Stock-Based Comp | 6.29 | 9.75 | 27.00 | 45.39 | 53.84 |
| Δ Working Cap & Other | (23.05) | (95.50) | (15.37) | 32.93 | (101.62) |
| Operating Cash Flow | (25.88) | (50.94) | (68.72) | (192.98) | (270.43) |
| CapEx | — | 0.00 | (0.25) | (1.22) | (4.19) |
| Other Investing | 0.95 | 18.15 | 8.87 | 125.09 | 207.15 |
| Investing Cash Flow | 0.95 | 18.15 | 8.62 | 123.87 | 202.96 |
| Stock Issuance | 4.42 | 1.47 | 9.35 | 2.14 | 21.89 |
| Other Financing | 14.88 | 14.63 | 49.93 | — | 31.19 |
| Financing Cash Flow | 19.30 | 16.10 | 59.28 | 2.01 | 53.08 |
| Free Cash Flow | — | (50.94) | (68.96) | (194.20) | (274.62) |
| 3/31/26 | 12/31/25 | 9/30/25 | 6/30/25 | |
|---|---|---|---|---|
| Current Ratio | 2.16 | 0.82 | 1.02 | 1.70 |
| Quick Ratio | — | 0.82 | 1.02 | 1.70 |
| Debt / Equity | -1.54 | -1.53 | -1.82 | -2.05 |
| EBITDA Margin % | (647.3%) | (157.6%) | (102.5%) | 19.5% |
| Working Capital | 6.53 | (2.71) | 0.38 | 10.21 |
| Net Debt | — | — | — | — |
| ROE % | 11.1% | 8.8% | 11.7% | (6.8%) |
| ROA % | (20.7%) | (16.8%) | (14.3%) | 6.5% |
| LTM | 12/31/25 | 12/31/24 | 12/31/23 | 12/31/22 | |
|---|---|---|---|---|---|
| Current Ratio | 2.16 | 0.82 | 0.48 | 0.72 | 3.74 |
| Quick Ratio | — | 0.82 | 0.40 | 0.65 | 3.72 |
| Debt / Equity | -1.54 | -1.53 | -2.12 | -2.67 | 1.97 |
| EBITDA Margin % | (25.8%) | 31.4% | (60.8%) | (3163.2%) | (432.4%) |
| Working Capital | 6.53 | (2.71) | (69.68) | (40.36) | 216.16 |
| Net Debt | — | — | — | — | — |
| ROE % | 25.4% | (84.9%) | 87.8% | 278.3% | (180.3%) |
| ROA % | (47.3%) | 161.5% | (78.3%) | (166.8%) | (60.7%) |
Insider activity (last 2 years)
| Date Filed | Reporter | Relationship | Trans. Date | Code | Shares | Price | Total Value |
|---|---|---|---|---|---|---|---|
| 2026-05-11 | Panacea Innovation Ltd | 10% Owner | 2026-05-07 | S | (313,446) | $10.10 | -$3,165,021 |
| 2026-05-11 | EcoR1 Capital, LLC | 10% Owner | 2026-05-07 | P | 507,407 | $9.35 | $4,744,255 |
| 2026-03-19 | Panacea Innovation Ltd | 10% Owner | 2026-03-17 | M | 259,163 | $0.00 | $26 |
| 2026-03-19 | Panacea Innovation Ltd | 10% Owner | 2026-03-17 | F | (5) | $5.23 | -$26 |
| 2026-03-19 | Panacea Innovation Ltd | 10% Owner | 2026-03-17 | M | (259,163) | $6.61 | -$1,713,042 |
| 2026-03-11 | Nguyen AnhCo | Director, Officer (President and CEO) | 2026-03-09 | A | 81,100 | — | $0 |
| 2026-03-11 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2026-03-09 | A | 20,300 | — | $0 |
| 2026-03-04 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2026-03-02 | S | (24) | $5.08 | -$122 |
| 2026-03-04 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2026-03-02 | S | (1,603) | $5.08 | -$8,145 |
| 2026-03-04 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2026-03-02 | S | (377) | $5.08 | -$1,916 |
| 2026-03-04 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2026-03-02 | S | (100) | $5.08 | -$508 |
| 2026-03-04 | Nguyen AnhCo | Director, Officer (President and CEO) | 2026-03-02 | S | (198) | $5.08 | -$1,006 |
| 2026-03-04 | Nguyen AnhCo | Director, Officer (President and CEO) | 2026-03-02 | S | (58) | $5.08 | -$295 |
| 2026-03-04 | Nguyen AnhCo | Director, Officer (President and CEO) | 2026-03-02 | S | (1,298) | $5.09 | -$6,602 |
| 2026-03-04 | Nguyen AnhCo | Director, Officer (President and CEO) | 2026-03-02 | S | (1,442) | $5.09 | -$7,335 |
| 2026-01-14 | Panacea Innovation Ltd | 10% Owner | 2026-01-12 | S | (80,554) | $6.07 | -$489,019 |
| 2025-12-01 | Panacea Innovation Ltd | 10% Owner | 2025-11-28 | M | 48,737 | $0.00 | $5 |
| 2025-12-01 | Panacea Innovation Ltd | 10% Owner | 2025-11-28 | F | (1) | $14.03 | -$14 |
| 2025-12-01 | Panacea Innovation Ltd | 10% Owner | 2025-11-28 | M | (48,737) | $6.61 | -$322,147 |
| 2025-11-19 | Nguyen AnhCo | Director, Officer (President and CEO) | 2025-11-17 | S | (2,859) | $13.19 | -$37,699 |
| 2025-11-19 | Nguyen AnhCo | Director, Officer (President and CEO) | 2025-11-17 | S | (56) | $13.19 | -$739 |
| 2025-11-19 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2025-11-17 | S | (1,645) | $13.19 | -$21,691 |
| 2025-11-19 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2025-11-17 | S | (85) | $13.19 | -$1,121 |
| 2025-11-19 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2025-11-17 | S | (74) | $13.19 | -$976 |
| 2025-08-20 | Nguyen AnhCo | Director, Officer (President and CEO) | 2025-08-18 | S | (57) | $11.61 | -$662 |
| 2025-08-20 | Nguyen AnhCo | Director, Officer (President and CEO) | 2025-08-18 | S | (1,281) | $11.62 | -$14,879 |
| 2025-08-20 | Nguyen AnhCo | Director, Officer (President and CEO) | 2025-08-18 | S | (1,620) | $11.62 | -$18,820 |
| 2025-08-20 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2025-08-18 | S | (55) | $11.61 | -$638 |
| 2025-08-20 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2025-08-18 | S | (86) | $11.61 | -$999 |
| 2025-08-20 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2025-08-18 | S | (1,668) | $11.61 | -$19,372 |
| 2025-08-19 | Panacea Innovation Ltd | 10% Owner | 2025-08-15 | P | 55,000 | $12.19 | $670,422 |
| 2025-07-21 | Panacea Innovation Ltd | 10% Owner | 2025-07-17 | P | 19,335 | $9.64 | $186,372 |
| 2025-06-12 | Gallagher Carol Giltner | Director | 2025-06-10 | A | 7,828 | — | $0 |
| 2025-06-12 | Fust Matthew K | Director | 2025-06-10 | A | 7,828 | — | $0 |
| 2025-06-12 | Touchon Pascal | Director | 2025-06-10 | A | 7,828 | — | $0 |
| 2025-06-12 | Roncarolo Maria Grazia | Director | 2025-06-10 | A | 7,828 | — | $0 |
| 2025-06-12 | MALLIK AMEET | Director | 2025-06-10 | A | 7,828 | — | $0 |
| 2025-06-12 | HEIDEN WILLIAM K | Director | 2025-06-10 | A | 7,828 | — | $0 |
| 2025-05-20 | Grant-Huerta Yanina | Officer (Chief Accounting Officer) | 2025-05-16 | S | (2,218) | $6.76 | -$15,000 |
| 2025-05-20 | Nguyen AnhCo | Director, Officer (President and CEO) | 2025-05-16 | S | (3,276) | $6.76 | -$22,156 |
| 2025-05-16 | Adiumentum Capital Fund I LP | Director, 10% Owner, Other (See remarks) | 2025-05-16 | A | 75,572 | $6.61 | $499,531 |
| 2025-05-16 | Adiumentum Capital Fund I LP | Director, 10% Owner, Other (See remarks) | 2025-05-16 | A | 227,000 | $6.61 | $1,500,447 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (1,900) | — | $-0 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (460) | — | $-0 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (496) | — | $-0 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (154) | — | $-0 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (381) | — | $-0 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (350) | — | $-0 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (262) | — | $-0 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (543) | — | $-0 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (331) | — | $-0 |
| 2025-04-02 | Hyllengren Eric J | Other (Former EVP, CFO & COO) | 2025-03-31 | D | (8,961) | — | $-0 |
| 2025-03-05 | Nguyen AnhCo | Director, Officer (President and CEO) | 2025-03-03 | S | (3,331) | $7.00 | -$23,307 |
| 2025-03-05 | Hyllengren Eric J | Officer (EVP, CFO and COO) | 2025-03-03 | S | (1,211) | $7.00 | -$8,473 |
| 2025-03-05 | Henrich Jill | Officer (EVP, Chief Regulatory Officer) | 2025-03-03 | S | (1,059) | $7.00 | -$7,410 |
| 2025-01-29 | Hyllengren Eric J | Officer (EVP, CFO and COO) | 2025-01-27 | A | 34,050 | — | $0 |
| 2024-11-20 | Henrich Jill | Officer (EVP, Chief Regulatory Officer) | 2024-11-18 | S | (1,000) | $11.20 | -$11,198 |
| 2024-11-20 | Hyllengren Eric J | Officer (EVP, CFO and COO) | 2024-11-18 | S | (1,364) | $11.20 | -$15,274 |
| 2024-11-20 | Nguyen AnhCo | Director, Officer (President and CEO) | 2024-11-18 | S | (1,664) | $11.20 | -$18,633 |
| 2024-09-11 | Nguyen AnhCo | Director, Officer (President and CEO) | 2024-09-09 | A | 45,000 | — | $0 |
| 2024-08-20 | Touchon Pascal | Director, Officer (President and CEO) | 2024-08-16 | S | (2,762) | $6.63 | -$18,309 |
| 2024-08-20 | Touchon Pascal | Director, Officer (President and CEO) | 2024-08-16 | S | (276) | $6.63 | -$1,830 |
| 2024-08-20 | Nguyen AnhCo | Officer (EVP, Chief Sci. & Tech Officer) | 2024-08-16 | S | (1,468) | $6.63 | -$9,731 |
| 2024-08-20 | Nguyen AnhCo | Officer (EVP, Chief Sci. & Tech Officer) | 2024-08-16 | S | (297) | $6.63 | -$1,969 |
| 2024-08-20 | Nguyen AnhCo | Officer (EVP, Chief Sci. & Tech Officer) | 2024-08-16 | S | (56) | $6.63 | -$371 |
| 2024-08-20 | Murugan Amar | Officer (EVP, Chief Legal Officer) | 2024-08-16 | S | (877) | $6.63 | -$5,814 |
| 2024-08-20 | Murugan Amar | Officer (EVP, Chief Legal Officer) | 2024-08-16 | S | (192) | $6.63 | -$1,273 |
| 2024-08-20 | Murugan Amar | Officer (EVP, Chief Legal Officer) | 2024-08-16 | S | (89) | $6.63 | -$590 |
| 2024-08-20 | Hyllengren Eric J | Officer (EVP, CFO) | 2024-08-16 | S | (1,041) | $6.63 | -$6,901 |
| 2024-08-20 | Hyllengren Eric J | Officer (EVP, CFO) | 2024-08-16 | S | (29) | $6.63 | -$192 |
| 2024-08-20 | Henrich Jill | Officer (EVP, Global Head RA & Quality) | 2024-08-16 | S | (831) | $6.63 | -$5,509 |
| 2024-08-20 | Henrich Jill | Officer (EVP, Global Head RA & Quality) | 2024-08-16 | S | (132) | $6.63 | -$875 |
| 2024-08-14 | Touchon Pascal | Director, Officer (President and CEO) | 2024-08-12 | D | (9,000) | — | $-0 |
| 2024-08-14 | Touchon Pascal | Director, Officer (President and CEO) | 2024-08-12 | D | (9,680) | — | $-0 |
| 2024-08-14 | Touchon Pascal | Director, Officer (President and CEO) | 2024-08-12 | D | (7,075) | — | $-0 |
| 2024-05-20 | Touchon Pascal | Director, Officer (President and CEO) | 2024-05-16 | S | (81,506) | $0.62 | -$50,289 |
| 2024-05-20 | Nguyen AnhCo | Officer (EVP, Chief Sci. & Tech Officer) | 2024-05-16 | S | (42,899) | $0.62 | -$26,469 |
| 2024-05-20 | Murugan Amar | Officer (EVP, Chief Legal Officer) | 2024-05-16 | S | (32,401) | $0.62 | -$19,991 |
| 2024-05-20 | Hyllengren Eric J | Officer (EVP, CFO) | 2024-05-16 | S | (28,648) | $0.62 | -$17,676 |
| 2024-05-20 | Henrich Jill | Officer (EVP, Global Head RA & Quality) | 2024-05-16 | S | (25,750) | $0.62 | -$15,888 |